首页 > 最新文献

Advances in respiratory medicine最新文献

英文 中文
Pharmacological Immunomodulation via Collagen-Polyvinylpyrrolidone or Pirfenidone Plays a Role in the Recovery of Patients with Severe COVID-19 Through Similar Mechanisms of Action Involving the JAK/STAT Signalling Pathway: A Pilot Study. 胶原-聚吡咯烷酮或吡非尼酮通过涉及JAK/STAT信号通路的类似作用机制在重症COVID-19患者康复中的药理免疫调节作用:一项初步研究
IF 2.3 Q3 RESPIRATORY SYSTEM Pub Date : 2025-07-18 DOI: 10.3390/arm93040024
Hugo Mendieta-Zerón, Esteban Cruz-Arenas, Salvador Díaz-Meza, Alejandro Cabrera-Wrooman, Edna Ayerim Mandujano-Tinoco, Rosa M Salgado, Hugo Tovar, Daniel Muñiz-García, Laura Julieta Orozco-Castañeda, Sonia Hernández-Enríquez, Miriam Deyanira Rodríguez-Piña, Ana Sarahí Mulia-Soto, José Meneses-Calderón, Paul Mondragón-Terán, Edgar Krötzsch

The therapeutic target of COVID-19 is focused on controlling inflammation and preventing fibrosis. Collagen-polyvinylpyrrolidone (collagen-PVP) and pirfenidone both have the ability to control the cytokine storm observed in rheumatic and fibrotic disorders. In this work, our aim was to understand the benefits of treatment with each of these drugs in patients with severe COVID-19. In total, 36 patients were treated with dexamethasone and enoxaparin, but 26 were allocated collagen-PVP or pirfenidone (n = 15 and 11, respectively); the clinical and metabolic effects were compared among them. Since pirfenidone works via transcriptional mechanisms, we performed a human genome microarray assay using RNA isolated from fibroblast and monocyte cultures treated with the biodrug, with the aim of hypothesising a possible mechanism of action for collagen-PVP. Our results showed that hospital stay duration, quick COVID-19 severity index (qCSI), and admission to the intensive care unit were statistically significantly lower (p < 0.02) in patients treated with collagen-PVP or pirfenidone when compared with the control group, and that only collagen-PVP normalised serum glucose at discharge. Ingenuity Pathway Analysis showed that the cell cycle, inflammation, and cell surface-extracellular matrix interactions could be regulated with collagen-PVP via the downmodulation of proinflammatory cytokines, while Th2 anti-inflammatory response signalling could be upregulated. Furthermore, the downregulation of some of the genes involved in nitric oxide production showed a possible control for JAK in the IFN-γ pathway, allowing for the possibility of controlling inflammation through the JAK/STAT pathway, as has been observed for pirfenidone and other immunomodulators, such as ruxolitinib.

新冠肺炎的治疗靶点主要集中在控制炎症和预防纤维化。胶原-聚乙烯吡咯烷酮(胶原- pvp)和吡非尼酮都有能力控制在风湿病和纤维化疾病中观察到的细胞因子风暴。在这项工作中,我们的目标是了解使用每种药物治疗严重COVID-19患者的益处。共有36例患者接受地塞米松和依诺肝素治疗,26例患者接受胶原- pvp或吡非尼酮治疗(n = 15和11);比较两组患者的临床及代谢效果。由于吡非尼酮通过转录机制起作用,我们使用从生物药物处理的成纤维细胞和单核细胞培养物中分离的RNA进行了人类基因组微阵列分析,目的是假设胶原- pvp的可能作用机制。我们的研究结果显示,与对照组相比,使用胶原- pvp或吡非尼酮治疗的患者住院时间、COVID-19快速严重程度指数(qCSI)和重症监护病房入院率均有统计学意义(p < 0.02),且仅使用胶原- pvp治疗的患者出院时血糖正常。匠心途径分析显示,胶原- pvp可以通过下调促炎细胞因子调控细胞周期、炎症和细胞表面-细胞外基质相互作用,而Th2抗炎反应信号可以上调。此外,参与一氧化氮产生的一些基因的下调表明,在IFN-γ途径中可能控制JAK,从而允许通过JAK/STAT途径控制炎症,正如在吡非尼酮和其他免疫调节剂(如ruxolitinib)中观察到的那样。
{"title":"Pharmacological Immunomodulation via Collagen-Polyvinylpyrrolidone or Pirfenidone Plays a Role in the Recovery of Patients with Severe COVID-19 Through Similar Mechanisms of Action Involving the JAK/STAT Signalling Pathway: A Pilot Study.","authors":"Hugo Mendieta-Zerón, Esteban Cruz-Arenas, Salvador Díaz-Meza, Alejandro Cabrera-Wrooman, Edna Ayerim Mandujano-Tinoco, Rosa M Salgado, Hugo Tovar, Daniel Muñiz-García, Laura Julieta Orozco-Castañeda, Sonia Hernández-Enríquez, Miriam Deyanira Rodríguez-Piña, Ana Sarahí Mulia-Soto, José Meneses-Calderón, Paul Mondragón-Terán, Edgar Krötzsch","doi":"10.3390/arm93040024","DOIUrl":"10.3390/arm93040024","url":null,"abstract":"<p><p>The therapeutic target of COVID-19 is focused on controlling inflammation and preventing fibrosis. Collagen-polyvinylpyrrolidone (collagen-PVP) and pirfenidone both have the ability to control the cytokine storm observed in rheumatic and fibrotic disorders. In this work, our aim was to understand the benefits of treatment with each of these drugs in patients with severe COVID-19. In total, 36 patients were treated with dexamethasone and enoxaparin, but 26 were allocated collagen-PVP or pirfenidone (<i>n</i> = 15 and 11, respectively); the clinical and metabolic effects were compared among them. Since pirfenidone works via transcriptional mechanisms, we performed a human genome microarray assay using RNA isolated from fibroblast and monocyte cultures treated with the biodrug, with the aim of hypothesising a possible mechanism of action for collagen-PVP. Our results showed that hospital stay duration, quick COVID-19 severity index (qCSI), and admission to the intensive care unit were statistically significantly lower (<i>p</i> < 0.02) in patients treated with collagen-PVP or pirfenidone when compared with the control group, and that only collagen-PVP normalised serum glucose at discharge. Ingenuity Pathway Analysis showed that the cell cycle, inflammation, and cell surface-extracellular matrix interactions could be regulated with collagen-PVP via the downmodulation of proinflammatory cytokines, while Th2 anti-inflammatory response signalling could be upregulated. Furthermore, the downregulation of some of the genes involved in nitric oxide production showed a possible control for JAK in the IFN-γ pathway, allowing for the possibility of controlling inflammation through the JAK/STAT pathway, as has been observed for pirfenidone and other immunomodulators, such as ruxolitinib.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"93 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12286056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comparison of Impulse Oscillometry and Spirometry by Percent Predicted in Identifying Uncontrolled Asthma. 脉冲振荡法与肺活量测定法在诊断未控制哮喘中的预测百分率比较。
IF 2.3 Q3 RESPIRATORY SYSTEM Pub Date : 2025-07-18 DOI: 10.3390/arm93040025
Chalerm Liwsrisakun, Chaicharn Pothirat, Athavudh Deesomchok, Pilaiporn Duangjit, Warawut Chaiwong

Background: The role of impulse oscillometry (IOS) in evaluating asthma control remains a challenge because the interpretation varies by many factors, including ethnicity. We aimed to assess the diagnostic contribution of spirometry and IOS, established from reference equations, in the detection of uncontrolled asthma.

Methods: This retrospective study was conducted in adult asthma subjects with normal spirometry. Uncontrolled asthma was defined as an Asthma Control Test (ACT) score ≤ 19. Receiver operating characteristic (ROC) curves were plotted to compare the diagnostic abilities of the %-predicted of heterogeneity of resistance at 5 Hz and 20 Hz (R5-R20) and the %-predicted of forced expiratory volume in the first second (FEV1) in detecting uncontrolled asthma. Multivariable risk regressions were performed to identify the %-predicted of R5-R20 as a predictor for uncontrolled asthma.

Results: The %-predicted of R5-R20 demonstrated a superior diagnostic ability for detecting uncontrolled asthma compared to the %-predicted FEV1, with the area under the ROC curves (AuROC) = 0.939 vs. 0.712, respectively, p < 0.001. The %-predicted R5R20 of ≥200 showed the highest AuROC for detecting uncontrolled asthma with an adjusted risk ratio of 10.86 (95%CI; 3.77, 31.29; p < 0.001).

Conclusions: IOS demonstrated better diagnostic ability for detecting uncontrolled asthma than spirometry.

背景:脉冲振荡测量(IOS)在评估哮喘控制中的作用仍然是一个挑战,因为其解释因许多因素而异,包括种族。我们的目的是评估肺活量测定法和由参考方程建立的IOS在检测未控制哮喘中的诊断贡献。方法:对肺活量正常的成人哮喘患者进行回顾性研究。未控制哮喘定义为哮喘控制测试(ACT)评分≤19分。绘制受试者工作特征(ROC)曲线,比较5hz和20hz阻力异质性的预测% (R5-R20)和第一秒用力呼气量(FEV1)的预测%对未控制哮喘的诊断能力。进行多变量风险回归,以确定R5-R20的预测百分比作为未控制哮喘的预测因子。结果:R5-R20的%-预测值比FEV1的%-预测值对未控制哮喘的诊断能力更强,ROC曲线下面积(AuROC)分别为0.939比0.712,p < 0.001。R5R20≥200的%预测值显示,检测未控制哮喘的AuROC最高,校正风险比为10.86 (95%CI;3.77、31.29;P < 0.001)。结论:IOS对未控制哮喘的诊断能力优于肺量测定法。
{"title":"A Comparison of Impulse Oscillometry and Spirometry by Percent Predicted in Identifying Uncontrolled Asthma.","authors":"Chalerm Liwsrisakun, Chaicharn Pothirat, Athavudh Deesomchok, Pilaiporn Duangjit, Warawut Chaiwong","doi":"10.3390/arm93040025","DOIUrl":"10.3390/arm93040025","url":null,"abstract":"<p><strong>Background: </strong>The role of impulse oscillometry (IOS) in evaluating asthma control remains a challenge because the interpretation varies by many factors, including ethnicity. We aimed to assess the diagnostic contribution of spirometry and IOS, established from reference equations, in the detection of uncontrolled asthma.</p><p><strong>Methods: </strong>This retrospective study was conducted in adult asthma subjects with normal spirometry. Uncontrolled asthma was defined as an Asthma Control Test (ACT) score ≤ 19. Receiver operating characteristic (ROC) curves were plotted to compare the diagnostic abilities of the %-predicted of heterogeneity of resistance at 5 Hz and 20 Hz (R5-R20) and the %-predicted of forced expiratory volume in the first second (FEV<sub>1</sub>) in detecting uncontrolled asthma. Multivariable risk regressions were performed to identify the %-predicted of R5-R20 as a predictor for uncontrolled asthma.</p><p><strong>Results: </strong>The %-predicted of R5-R20 demonstrated a superior diagnostic ability for detecting uncontrolled asthma compared to the %-predicted FEV<sub>1</sub>, with the area under the ROC curves (AuROC) = 0.939 vs. 0.712, respectively, <i>p</i> < 0.001. The %-predicted R5R20 of ≥200 showed the highest AuROC for detecting uncontrolled asthma with an adjusted risk ratio of 10.86 (95%CI; 3.77, 31.29; <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>IOS demonstrated better diagnostic ability for detecting uncontrolled asthma than spirometry.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"93 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12285965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imaging and Laboratory Results as Predictors of the Course of COVID-19. 影像学和实验室结果作为COVID-19病程的预测指标。
IF 2.3 Q3 RESPIRATORY SYSTEM Pub Date : 2025-07-01 DOI: 10.3390/arm93040022
Ewelina Tobiczyk, Hanna Maria Winiarska, Daria Springer, Aleksandra Ludziejewska, Ewa Wysocka, Szymon Skoczyński, Szczepan Cofta

Background: COVID-19 most often affects the respiratory system and may manifest as acute respiratory failure requiring the use of non-invasive respiratory support (NIRS). The aim of this study was to find predictors based on laboratory results and chest computed tomography (CT) scans performed on admission to the hospital indicating the need for NIRS and predicting mortality after hospital discharge.

Methods: We retrospectively analysed data from consecutive patients hospitalised in the Pulmonology Department of the Temporary COVID Hospital in Poznan from 1 February 2021 to 31 March 2022. Upon admission to the department, the patients underwent a series of laboratory blood tests and high-resolution chest CT scan.

Results: The study group included 282 patients, with an average age of 60.0 ± 15.0 years. In total, 54 (53%) patients of 101 requiring NIRS died from various causes or required intubation. Patients who required NIRS were significantly older and had more severe changes in the lung parenchyma. They had higher white blood cell and neutrophil counts and lower lymphocyte counts, as well as higher concentrations of D-dimer, CRP, PCT, and IL-6 and greater activities of LDH and AST.

Conclusions: Laboratory tests and chest CT performed on hospital admission may be useful to rapidly identify patients at higher risk for severe disease.

背景:COVID-19最常影响呼吸系统,可能表现为急性呼吸衰竭,需要使用无创呼吸支持(NIRS)。本研究的目的是寻找基于实验室结果和入院时进行的胸部计算机断层扫描(CT)的预测因素,表明需要近红外光谱并预测出院后的死亡率。方法:回顾性分析2021年2月1日至2022年3月31日在波兹南临时COVID医院肺病科连续住院的患者数据。入院后,患者接受了一系列实验室血液检查和高分辨率胸部CT扫描。结果:研究组纳入282例患者,平均年龄60.0±15.0岁。101例患者中,54例(53%)因各种原因或需要插管而死亡。需要近红外光谱的患者明显年龄较大,肺实质改变更严重。他们白细胞和中性粒细胞计数较高,淋巴细胞计数较低,d -二聚体、CRP、PCT和IL-6浓度较高,LDH和ast活性较高。结论:入院时进行的实验室检查和胸部CT可能有助于快速识别严重疾病高风险患者。
{"title":"Imaging and Laboratory Results as Predictors of the Course of COVID-19.","authors":"Ewelina Tobiczyk, Hanna Maria Winiarska, Daria Springer, Aleksandra Ludziejewska, Ewa Wysocka, Szymon Skoczyński, Szczepan Cofta","doi":"10.3390/arm93040022","DOIUrl":"10.3390/arm93040022","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 most often affects the respiratory system and may manifest as acute respiratory failure requiring the use of non-invasive respiratory support (NIRS). The aim of this study was to find predictors based on laboratory results and chest computed tomography (CT) scans performed on admission to the hospital indicating the need for NIRS and predicting mortality after hospital discharge.</p><p><strong>Methods: </strong>We retrospectively analysed data from consecutive patients hospitalised in the Pulmonology Department of the Temporary COVID Hospital in Poznan from 1 February 2021 to 31 March 2022. Upon admission to the department, the patients underwent a series of laboratory blood tests and high-resolution chest CT scan.</p><p><strong>Results: </strong>The study group included 282 patients, with an average age of 60.0 ± 15.0 years. In total, 54 (53%) patients of 101 requiring NIRS died from various causes or required intubation. Patients who required NIRS were significantly older and had more severe changes in the lung parenchyma. They had higher white blood cell and neutrophil counts and lower lymphocyte counts, as well as higher concentrations of D-dimer, CRP, PCT, and IL-6 and greater activities of LDH and AST.</p><p><strong>Conclusions: </strong>Laboratory tests and chest CT performed on hospital admission may be useful to rapidly identify patients at higher risk for severe disease.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"93 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12285937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Invasive Mechanical Ventilation on the Lung Microbiome. 有创机械通气对肺微生物组的影响。
IF 2.3 Q3 RESPIRATORY SYSTEM Pub Date : 2025-07-01 DOI: 10.3390/arm93040023
Jose Luis Estela-Zape, Valeria Sanclemente-Cardoza, Maria Alejandra Espinosa-Cifuentes, Leidy Tatiana Ordoñez-Mora

The lung microbiota is integral to maintaining microenvironmental homeostasis, influencing immune regulation, host defense against pathogens, and overall respiratory health. The dynamic interplay among the lung microbiota emphasizes their significance in shaping the respiratory milieu and potential impact on diverse pulmonary affections. This investigation aimed to identify the effects of invasive mechanical ventilation on the lung microbiome. Materials and Methods: A systematic review was conducted with registration number CRD42023461618, based on a search of PubMed, SCOPUS, and Web of Science databases, in line with the PRISMA guidelines. To achieve this, "(mechanical ventilation) AND (microbiota)" was used as the search term, replicable across all databases. The closing date of the search was 12 March 2025, and the evidence was scored using the MINORS scale. Results: A total of 16 studies were included, with patients aged 13.6 months to 76 years, predominantly male (64.2%). Common ICU admission diagnoses requiring invasive mechanical ventilation (IMV) included pneumonia, acute respiratory failure, and COVID-19. IMV was associated with reduced lung microbiota diversity and an increased prevalence of pathogenic bacteria, including Prevotella, Streptococcus, Staphylococcus, Pseudomonas, and Acinetobacter. The most frequently used antibiotics were cephalosporins, aminoglycosides, and penicillins. IMV-induced pulmonary dysbiosis correlated with higher infection risk and mortality, particularly in pneumonia and COVID-19 cases. Factors such as antimicrobial therapy, enteral nutrition, and systemic inflammation contributed to these alterations. Conclusions: Invasive mechanical ventilation has been associated with the development of alterations in the respiratory microbiome, resulting in reduced diversity of lung microorganisms.

肺微生物群对于维持微环境稳态、影响免疫调节、宿主对病原体的防御和整体呼吸系统健康是不可或缺的。肺部微生物群之间的动态相互作用强调了它们在形成呼吸环境中的重要性以及对多种肺部疾病的潜在影响。本研究旨在确定有创机械通气对肺微生物组的影响。材料和方法:根据PRISMA指南,对PubMed、SCOPUS和Web of Science数据库进行检索,进行系统评价,注册号为CRD42023461618。为了实现这一点,使用“(机械通气)和(微生物群)”作为搜索词,可在所有数据库中复制。搜索截止日期为2025年3月12日,并使用未成年人量表对证据进行评分。结果:共纳入16项研究,患者年龄为13.6个月至76岁,以男性为主(64.2%)。ICU入院时需要有创机械通气(IMV)的常见诊断包括肺炎、急性呼吸衰竭和COVID-19。IMV与肺部微生物群多样性降低和致病菌患病率增加有关,包括普雷沃氏菌、链球菌、葡萄球菌、假单胞菌和不动杆菌。最常用的抗生素是头孢菌素、氨基糖苷类和青霉素类。imv引起的肺生态失调与较高的感染风险和死亡率相关,特别是在肺炎和COVID-19病例中。抗菌治疗、肠内营养和全身性炎症等因素导致了这些改变。结论:有创机械通气与呼吸微生物组改变的发展有关,导致肺部微生物多样性降低。
{"title":"Impact of Invasive Mechanical Ventilation on the Lung Microbiome.","authors":"Jose Luis Estela-Zape, Valeria Sanclemente-Cardoza, Maria Alejandra Espinosa-Cifuentes, Leidy Tatiana Ordoñez-Mora","doi":"10.3390/arm93040023","DOIUrl":"10.3390/arm93040023","url":null,"abstract":"<p><p>The lung microbiota is integral to maintaining microenvironmental homeostasis, influencing immune regulation, host defense against pathogens, and overall respiratory health. The dynamic interplay among the lung microbiota emphasizes their significance in shaping the respiratory milieu and potential impact on diverse pulmonary affections. This investigation aimed to identify the effects of invasive mechanical ventilation on the lung microbiome. <i>Materials and Methods</i>: A systematic review was conducted with registration number CRD42023461618, based on a search of PubMed, SCOPUS, and Web of Science databases, in line with the PRISMA guidelines. To achieve this, \"(mechanical ventilation) AND (microbiota)\" was used as the search term, replicable across all databases. The closing date of the search was 12 March 2025, and the evidence was scored using the MINORS scale. <i>Results</i>: A total of 16 studies were included, with patients aged 13.6 months to 76 years, predominantly male (64.2%). Common ICU admission diagnoses requiring invasive mechanical ventilation (IMV) included pneumonia, acute respiratory failure, and COVID-19. IMV was associated with reduced lung microbiota diversity and an increased prevalence of pathogenic bacteria, including <i>Prevotella</i>, <i>Streptococcus</i>, <i>Staphylococcus</i>, <i>Pseudomonas</i>, and <i>Acinetobacter</i>. The most frequently used antibiotics were cephalosporins, aminoglycosides, and penicillins. IMV-induced pulmonary dysbiosis correlated with higher infection risk and mortality, particularly in pneumonia and COVID-19 cases. Factors such as antimicrobial therapy, enteral nutrition, and systemic inflammation contributed to these alterations. <i>Conclusions</i>: Invasive mechanical ventilation has been associated with the development of alterations in the respiratory microbiome, resulting in reduced diversity of lung microorganisms.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"93 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12286237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Comparative Effectiveness of Mepolizumab and Benralizumab in the Treatment of Eosinophilic Asthma. Mepolizumab与Benralizumab治疗嗜酸性哮喘的疗效比较。
IF 2.3 Q3 RESPIRATORY SYSTEM Pub Date : 2025-06-20 DOI: 10.3390/arm93040021
Aleksandra Niemiec-Górska, Olga Branicka, Paula Olszewska, Sylwia Mielcarska, Joanna Glück, Barbara Rymarczyk, Radosław Gawlik

Background: Severe asthma is associated with significant morbidity and risk of complications. Some patients, suffering from eosinophilic asthma, may benefit from biological therapies, especially anti IL-5 (anti-interleukin-5). The purpose of the study was to compare the efficacy evaluation of mepolizumab and benralizumab in the treatment of eosinophilic asthma.

Methods: A retrospective, single-centre study including 59 patients with severe eosinophilic asthma treated with biologics (mepolizumab and benralizumab). Clinical outcomes, including peripheral blood morphotic characteristics, spirometry parameters, asthma control questionnaire (ACQ), mini-Asthma Quality of Life Questionnaire (mini-AQLQ) scores, daily oral corticosteroid use, body mass index, exacerbation rate, and exercise tolerance, were examined at the beginning and after 6 months of biological treatment.

Results: A total of 38 patients were treated with mepolizumab and 21 with benralizumab. Significant improvements (p < 0.05) in eosinophil count, required daily dose of glucocorticoids, ACQ, mini-AQLQ scores, and exacerbation rate were observed in both groups after six months of treatment. There was no statistical difference (p < 0.05) in the abovementioned parameters between the groups.

Conclusions: In patients with severe eosinophilic asthma, mepolizumab and benralizumab were associated with significant improvements in clinical state. Patients with type 2 asthma will benefit from the therapy with both anti-IL5 biologic drugs.

背景:严重哮喘与显著的发病率和并发症风险相关。一些患有嗜酸性粒细胞哮喘的患者可能受益于生物治疗,特别是抗IL-5(抗白细胞介素-5)。本研究的目的是比较mepolizumab和benralizumab治疗嗜酸性哮喘的疗效评价。方法:一项回顾性、单中心研究,包括59例使用生物制剂(mepolizumab和benralizumab)治疗的严重嗜酸性粒细胞哮喘患者。临床结果,包括外周血形态特征、肺活量测定参数、哮喘控制问卷(ACQ)、迷你哮喘生活质量问卷(mini-AQLQ)评分、每日口服皮质类固醇使用、体重指数、加重率和运动耐量,在生物治疗开始和6个月后进行检查。结果:共有38例患者接受美polizumab治疗,21例患者接受贝纳利珠单抗治疗。治疗6个月后,两组患者的嗜酸性粒细胞计数、糖皮质激素日剂量、ACQ、mini-AQLQ评分及加重率均有显著改善(p < 0.05)。各组间上述参数比较,差异均无统计学意义(p < 0.05)。结论:在重度嗜酸性粒细胞哮喘患者中,mepolizumab和benralizumab与临床状态的显著改善相关。2型哮喘患者将受益于抗il - 5生物药物的治疗。
{"title":"The Comparative Effectiveness of Mepolizumab and Benralizumab in the Treatment of Eosinophilic Asthma.","authors":"Aleksandra Niemiec-Górska, Olga Branicka, Paula Olszewska, Sylwia Mielcarska, Joanna Glück, Barbara Rymarczyk, Radosław Gawlik","doi":"10.3390/arm93040021","DOIUrl":"https://doi.org/10.3390/arm93040021","url":null,"abstract":"<p><strong>Background: </strong>Severe asthma is associated with significant morbidity and risk of complications. Some patients, suffering from eosinophilic asthma, may benefit from biological therapies, especially anti IL-5 (anti-interleukin-5). The purpose of the study was to compare the efficacy evaluation of mepolizumab and benralizumab in the treatment of eosinophilic asthma.</p><p><strong>Methods: </strong>A retrospective, single-centre study including 59 patients with severe eosinophilic asthma treated with biologics (mepolizumab and benralizumab). Clinical outcomes, including peripheral blood morphotic characteristics, spirometry parameters, asthma control questionnaire (ACQ), mini-Asthma Quality of Life Questionnaire (mini-AQLQ) scores, daily oral corticosteroid use, body mass index, exacerbation rate, and exercise tolerance, were examined at the beginning and after 6 months of biological treatment.</p><p><strong>Results: </strong>A total of 38 patients were treated with mepolizumab and 21 with benralizumab. Significant improvements (<i>p</i> < 0.05) in eosinophil count, required daily dose of glucocorticoids, ACQ, mini-AQLQ scores, and exacerbation rate were observed in both groups after six months of treatment. There was no statistical difference (<i>p</i> < 0.05) in the abovementioned parameters between the groups.</p><p><strong>Conclusions: </strong>In patients with severe eosinophilic asthma, mepolizumab and benralizumab were associated with significant improvements in clinical state. Patients with type 2 asthma will benefit from the therapy with both anti-IL5 biologic drugs.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"93 4","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12382853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144938743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating Obstructive Sleep Apnea Utilizing Arterial Tonometry in Individuals with Cystic Fibrosis. 利用动脉血压计在囊性纤维化患者中评估阻塞性睡眠呼吸暂停。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2025-06-17 DOI: 10.3390/arm93030020
Michelle Chiu, Bethany Bartley, Elizabeth Gootkind, Salma Batool-Anwar, Donald G Keamy, Thomas Bernard Kinane, Lael M Yonker, Kevin S Gipson

Poor sleep quality and excessive daytime sleepiness are commonly reported by individuals with cystic fibrosis. The potential impact of comorbid sleep-disordered breathing (SDB), particularly obstructive sleep apnea (OSA), has not been extensively studied in the CF population. At present, there are no specific recommendations available to help clinicians identify patients with CF who are at increased risk of sleep disorders. Home sleep apnea testing using a validated peripheral arterial tonometry (PAT) device may offer an accurate diagnosis of OSA in a more convenient and low-cost method than in-lab polysomnography. In this single-center study of 19 adults with CF, we found an increased prevalence of OSA among individuals with CF compared to general population estimates. Although associations with an FEV < 70% predicted and a modified Mallampati score ≥ 3 were observed, these odds ratios did not reach statistical significance, likely reflecting limited power in this small pilot sample. There was no association found between the self-reported presence of nocturnal cough or snoring and OSA. We also found no association between OSA and abnormal scores on commonly used, validated sleep questionnaires, suggesting that CF-specific scales may be needed for effective screening in the CF clinic.

囊性纤维化患者通常报告睡眠质量差和白天过度嗜睡。共病性睡眠呼吸障碍(SDB),特别是阻塞性睡眠呼吸暂停(OSA)的潜在影响尚未在CF人群中得到广泛研究。目前,尚无具体的建议来帮助临床医生识别有睡眠障碍风险增加的CF患者。使用经过验证的外周动脉压计(PAT)设备进行家庭睡眠呼吸暂停测试,可能比实验室多导睡眠图更方便、更低成本地提供OSA的准确诊断。在这项针对19名成年CF患者的单中心研究中,我们发现与一般人群相比,CF患者的OSA患病率有所增加。虽然观察到FEV < 70%预测和改良Mallampati评分≥3的相关性,但这些比值比没有达到统计学意义,可能反映了在这个小样本中有限的力量。没有发现自我报告的夜间咳嗽或打鼾与阻塞性睡眠呼吸暂停综合症之间的联系。我们还发现,在常用的、经过验证的睡眠问卷中,OSA与异常评分之间没有关联,这表明CF特异性量表可能需要在CF临床中进行有效筛查。
{"title":"Evaluating Obstructive Sleep Apnea Utilizing Arterial Tonometry in Individuals with Cystic Fibrosis.","authors":"Michelle Chiu, Bethany Bartley, Elizabeth Gootkind, Salma Batool-Anwar, Donald G Keamy, Thomas Bernard Kinane, Lael M Yonker, Kevin S Gipson","doi":"10.3390/arm93030020","DOIUrl":"10.3390/arm93030020","url":null,"abstract":"<p><p>Poor sleep quality and excessive daytime sleepiness are commonly reported by individuals with cystic fibrosis. The potential impact of comorbid sleep-disordered breathing (SDB), particularly obstructive sleep apnea (OSA), has not been extensively studied in the CF population. At present, there are no specific recommendations available to help clinicians identify patients with CF who are at increased risk of sleep disorders. Home sleep apnea testing using a validated peripheral arterial tonometry (PAT) device may offer an accurate diagnosis of OSA in a more convenient and low-cost method than in-lab polysomnography. In this single-center study of 19 adults with CF, we found an increased prevalence of OSA among individuals with CF compared to general population estimates. Although associations with an FEV < 70% predicted and a modified Mallampati score ≥ 3 were observed, these odds ratios did not reach statistical significance, likely reflecting limited power in this small pilot sample. There was no association found between the self-reported presence of nocturnal cough or snoring and OSA. We also found no association between OSA and abnormal scores on commonly used, validated sleep questionnaires, suggesting that CF-specific scales may be needed for effective screening in the CF clinic.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"93 3","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12189706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Harnessing Natural Product Compounds to Target Dormancy Survival Regulator (DosR) in Latent Tuberculosis Infection (LTBI): An In Silico Strategy Against Dormancy. 利用天然产物化合物靶向潜伏性结核感染(LTBI)的休眠生存调节剂(DosR):一种对抗休眠的计算机策略。
IF 2.3 Q3 RESPIRATORY SYSTEM Pub Date : 2025-06-16 DOI: 10.3390/arm93030019
Mandeep Chouhan, Mukesh Kumar, Vivek Dhar Dwivedi, Vivek Kumar Kashyap, Himanshu Narayan Singh, Sanjay Kumar

Dormancy occurs when Mycobacterium tuberculosis (Mtb) enters a non-replicating and metabolically inactive state in response to hostile environment. During this state, it is highly resistant to conventional antibiotics, which increase the urgency to develop new potential drugs against dormant bacilli. In view of this, the dormancy survival regulator (DosR) protein is thought to be an essential component that plays a key role in bacterial adaptation to dormancy during hypoxic conditions. Herein, the NP-lib database containing natural product compounds was screened virtually against the binding site of the DosR protein using the MTiopen screen web server. A series of computational analyses were performed, including redocking, intermolecular interaction analysis, and MDS, followed by binding free energy analysis. Through screening, 1000 natural product compounds were obtained with docking energy ranging from -8.5 to -4.1 kcal/mol. The top four lead compounds were then selected for further investigation. On comparative analysis of intermolecular interaction, dynamics simulation and MM/GBSA calculation revealed that M3 docked with the DosR protein (docking score = -8.1 kcal/mol, RMSD = ~7 Å and ΔG Bind = -53.51 kcal/mol) exhibited stronger stability than reference compound Ursolic acid (docking score = -6.2 kcal/mol, RMSD = ~13.5 Å and ΔG Bind = -44.51 kcal/mol). Hence, M3 is recommended for further validation through in vitro and in vivo studies against latent tuberculosis infection.

当结核分枝杆菌(Mtb)进入非复制和代谢不活跃状态以应对恶劣环境时,就会发生休眠。在这种状态下,它对常规抗生素具有高度耐药性,这增加了开发新的潜在药物对抗休眠杆菌的紧迫性。鉴于此,休眠存活调节蛋白(DosR)被认为是细菌在缺氧条件下适应休眠的重要组成部分。本文使用MTiopen筛选web服务器对含有天然产物化合物的NP-lib数据库进行了针对DosR蛋白结合位点的虚拟筛选。进行了一系列的计算分析,包括重新对接、分子间相互作用分析和MDS,然后进行了结合自由能分析。筛选得到1000个对接能在-8.5 ~ -4.1 kcal/mol之间的天然产物化合物。然后选择前四种先导化合物进行进一步研究。分子间相互作用对比分析、动力学模拟和MM/GBSA计算表明,与DosR蛋白对接的M3(对接评分= -8.1 kcal/mol, RMSD = ~7 Å和ΔG Bind = -53.51 kcal/mol)比参比化合物熊果酸(对接评分= -6.2 kcal/mol, RMSD = ~13.5 Å和ΔG Bind = -44.51 kcal/mol)具有更强的稳定性。因此,建议通过体内和体外研究进一步验证M3对潜伏性结核感染的作用。
{"title":"Harnessing Natural Product Compounds to Target Dormancy Survival Regulator (DosR) in Latent Tuberculosis Infection (LTBI): An In Silico Strategy Against Dormancy.","authors":"Mandeep Chouhan, Mukesh Kumar, Vivek Dhar Dwivedi, Vivek Kumar Kashyap, Himanshu Narayan Singh, Sanjay Kumar","doi":"10.3390/arm93030019","DOIUrl":"10.3390/arm93030019","url":null,"abstract":"<p><p>Dormancy occurs when <i>Mycobacterium tuberculosis</i> (Mtb) enters a non-replicating and metabolically inactive state in response to hostile environment. During this state, it is highly resistant to conventional antibiotics, which increase the urgency to develop new potential drugs against dormant bacilli. In view of this, the dormancy survival regulator (DosR) protein is thought to be an essential component that plays a key role in bacterial adaptation to dormancy during hypoxic conditions. Herein, the NP-lib database containing natural product compounds was screened virtually against the binding site of the DosR protein using the MTiopen screen web server. A series of computational analyses were performed, including redocking, intermolecular interaction analysis, and MDS, followed by binding free energy analysis. Through screening, 1000 natural product compounds were obtained with docking energy ranging from -8.5 to -4.1 kcal/mol. The top four lead compounds were then selected for further investigation. On comparative analysis of intermolecular interaction, dynamics simulation and MM/GBSA calculation revealed that M3 docked with the DosR protein (docking score = -8.1 kcal/mol, RMSD = ~7 Å and ΔG Bind = -53.51 kcal/mol) exhibited stronger stability than reference compound Ursolic acid (docking score = -6.2 kcal/mol, RMSD = ~13.5 Å and ΔG Bind = -44.51 kcal/mol). Hence, M3 is recommended for further validation through in vitro and in vivo studies against latent tuberculosis infection.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"93 3","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12190169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medication Recommendation, Counseling, and Pricing for Nasal Sprays in German Community Pharmacies: A Simulated Patient Investigation. 德国社区药房鼻喷雾剂的药物推荐、咨询和定价:一项模拟患者调查。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2025-06-13 DOI: 10.3390/arm93030018
Bernhard Langer, Christian Kunow, Tim Dethloff, Sarah George

For the self-medication of nasal congestion following a common cold, decongestant nasal sprays can be recommended according to the medicine guidelines. In Germany, these are only available in community pharmacies (CPs) with free pricing. The aim was to analyze the medication recommendation, counseling, and pricing. A covert simulated patient study, internationally recognized as the "gold standard", was conducted in all CPs of two medium-sized cities in north-eastern Germany. Each CP was visited twice (86 visits) with the identical scenario by one female and one male simulated patient. At the beginning, they asked for a nasal spray and, when asked, stated that they had had nasal congestion for three days. Slightly more than half (54.7%, 47/86) of the recommended nasal sprays were free of preservatives. The median counseling score was 2.0 out of 8 points, with a significantly higher score observed for the female SP (p = 0.004). Information on the maximum intake duration of five days recommended in the German pharmacy guideline was not provided during any visits. The prices varied in total from EUR 1.95 to EUR 6.22. Therefore, measures by the legislator and the chambers of pharmacists are necessary to sustainably improve the medication recommendation, the counseling, and the price transparency.

对于普通感冒后鼻塞的自我治疗,可以根据药物指南推荐使用减充血剂鼻喷雾剂。在德国,这些药物只在社区药房(CPs)免费提供。目的是分析药物推荐、咨询和定价。在德国东北部两个中等城市的所有CPs中进行了一项隐蔽的模拟患者研究,该研究被国际公认为“金标准”。每个CP被访问两次(86次),由一名女性和一名男性模拟患者在相同的场景下访问。一开始,他们要求使用鼻腔喷雾剂,当被问及时,他们说他们已经鼻塞三天了。略多于一半(54.7%,47/86)的推荐鼻腔喷雾剂不含防腐剂。咨询得分中位数为2.0分(满分为8分),女性SP的得分明显更高(p = 0.004)。在任何访问期间,没有提供德国药房指南中建议的最长摄入时间为5天的信息。价格从1.95欧元到6.22欧元不等。因此,需要立法者和药师协会采取措施,持续改善药物推荐、咨询和价格透明度。
{"title":"Medication Recommendation, Counseling, and Pricing for Nasal Sprays in German Community Pharmacies: A Simulated Patient Investigation.","authors":"Bernhard Langer, Christian Kunow, Tim Dethloff, Sarah George","doi":"10.3390/arm93030018","DOIUrl":"10.3390/arm93030018","url":null,"abstract":"<p><p>For the self-medication of nasal congestion following a common cold, decongestant nasal sprays can be recommended according to the medicine guidelines. In Germany, these are only available in community pharmacies (CPs) with free pricing. The aim was to analyze the medication recommendation, counseling, and pricing. A covert simulated patient study, internationally recognized as the \"gold standard\", was conducted in all CPs of two medium-sized cities in north-eastern Germany. Each CP was visited twice (86 visits) with the identical scenario by one female and one male simulated patient. At the beginning, they asked for a nasal spray and, when asked, stated that they had had nasal congestion for three days. Slightly more than half (54.7%, 47/86) of the recommended nasal sprays were free of preservatives. The median counseling score was 2.0 out of 8 points, with a significantly higher score observed for the female SP (<i>p</i> = 0.004). Information on the maximum intake duration of five days recommended in the German pharmacy guideline was not provided during any visits. The prices varied in total from EUR 1.95 to EUR 6.22. Therefore, measures by the legislator and the chambers of pharmacists are necessary to sustainably improve the medication recommendation, the counseling, and the price transparency.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"93 3","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12190096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Utility of ctDNA Analysis in Lung Cancer-A Review. ctDNA分析在肺癌中的临床应用综述。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2025-06-12 DOI: 10.3390/arm93030017
Kamil Makar, Agata Wróbel, Adam Antczak, Damian Tworek

Circulating free DNA (cfDNA) is genetic material released from various cells into bodily fluids. Among its fractions, circulating tumor DNA (ctDNA) originates from tumor cells and reflects their genetic material, including mutations and epigenetic changes. Methods commonly employed for detecting ctDNA in blood include next-generation sequencing (NGS) and various types of PCR. The presence of ctDNA can be utilized in liquid biopsies for many diagnostic purposes related to various cancers. It is a minimally invasive method of sampling molecular compounds from tumor cells. In this paper, we focus on current knowledge regarding the liquid biopsy of blood ctDNA in the context of lung cancer, one of the leading causes of cancer-related mortality. Currently, as a clinically approved method, liquid biopsy serves as a complementary technique in NSCLC diagnostic and genetic profiling. Other applications of liquid biopsy that are still being investigated include the detection of minimal residual disease (MRD) after curative treatment and response monitoring to systemic treatment. This review discusses current and future potential directions for the development and implementation of ctDNA for patients with NSCLC.

循环游离DNA (cfDNA)是从各种细胞释放到体液中的遗传物质。其中循环肿瘤DNA (ctDNA)来源于肿瘤细胞,反映肿瘤细胞的遗传物质,包括突变和表观遗传变化。通常用于检测血液中ctDNA的方法包括下一代测序(NGS)和各种类型的PCR。ctDNA的存在可以在液体活检中用于与各种癌症相关的许多诊断目的。这是一种从肿瘤细胞中取样分子化合物的微创方法。在本文中,我们关注的是目前关于肺癌背景下血液ctDNA液体活检的知识,肺癌是癌症相关死亡的主要原因之一。目前,液体活检作为一种临床批准的方法,在非小细胞肺癌诊断和遗传谱分析中作为一种补充技术。液体活检的其他应用仍在研究中,包括治疗后微小残留病(MRD)的检测和对全身治疗的反应监测。这篇综述讨论了目前和未来ctDNA在非小细胞肺癌患者中的发展和实施的潜在方向。
{"title":"Clinical Utility of ctDNA Analysis in Lung Cancer-A Review.","authors":"Kamil Makar, Agata Wróbel, Adam Antczak, Damian Tworek","doi":"10.3390/arm93030017","DOIUrl":"10.3390/arm93030017","url":null,"abstract":"<p><p>Circulating free DNA (cfDNA) is genetic material released from various cells into bodily fluids. Among its fractions, circulating tumor DNA (ctDNA) originates from tumor cells and reflects their genetic material, including mutations and epigenetic changes. Methods commonly employed for detecting ctDNA in blood include next-generation sequencing (NGS) and various types of PCR. The presence of ctDNA can be utilized in liquid biopsies for many diagnostic purposes related to various cancers. It is a minimally invasive method of sampling molecular compounds from tumor cells. In this paper, we focus on current knowledge regarding the liquid biopsy of blood ctDNA in the context of lung cancer, one of the leading causes of cancer-related mortality. Currently, as a clinically approved method, liquid biopsy serves as a complementary technique in NSCLC diagnostic and genetic profiling. Other applications of liquid biopsy that are still being investigated include the detection of minimal residual disease (MRD) after curative treatment and response monitoring to systemic treatment. This review discusses current and future potential directions for the development and implementation of ctDNA for patients with NSCLC.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"93 3","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12189613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on Giraldo-Ocampo et al. B Cell Subsets in Colombian Adults with Predominantly Antibody Deficiencies, Bronchiectasis or Recurrent Pneumonia. Adv. Respir. Med. 2022, 90, 254-266. 对吉拉尔多-奥坎波等人的评论。哥伦比亚成人主要抗体缺乏、支气管扩张或复发性肺炎的B细胞亚群放置和。中国医学杂志,2016,31(4):544 - 544。
IF 1.8 Q3 RESPIRATORY SYSTEM Pub Date : 2025-06-09 DOI: 10.3390/arm93030015
Behnam Shafaei

I am writing regarding the article titled "B Cell Subsets in Colombian Adults with Predominantly Antibody Deficiencies, Bronchiectasis or Recurrent Pneumonia" [...].

我写这篇文章的题目是“哥伦比亚成人主要有抗体缺乏、支气管扩张或复发性肺炎的B细胞亚群”[…]
{"title":"Comment on Giraldo-Ocampo et al. B Cell Subsets in Colombian Adults with Predominantly Antibody Deficiencies, Bronchiectasis or Recurrent Pneumonia. <i>Adv. Respir. Med.</i> 2022, <i>90</i>, 254-266.","authors":"Behnam Shafaei","doi":"10.3390/arm93030015","DOIUrl":"10.3390/arm93030015","url":null,"abstract":"<p><p>I am writing regarding the article titled \"B Cell Subsets in Colombian Adults with Predominantly Antibody Deficiencies, Bronchiectasis or Recurrent Pneumonia\" [...].</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"93 3","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12189335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Advances in respiratory medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1